Distinct, measurable patterns of immune activation characterized by specific biomarker profiles, cellular compositions, and functional outcomes. Range from acute high-amplitude responses (pathogen clearance) through chronic low-grade metabolic inflammation (metaflammation) to resolution-deficient states where inflammation persists despite tissue healing. Each state reflects different triggers, regulatory mechanisms, and therapeutic responsiveness, making phenotype identification essential for precision clinical intervention.
Imagine a fire department with different response modes. Acute inflammation is the full five-alarm response: every truck, siren blaring, massive water pressure, complete focus on extinguishing the fire. It's dramatic, expensive, exhausting—but it works fast and then everyone goes home. Chronic low-grade inflammation is like having one fire truck idling outside your house 24/7, engine running, crew on edge, occasional spurts of water through the windows. It never fully mobilizes, never fully stands down—just burns fuel and creates background damage. Metaflammation is when your central heating system starts emitting smoke because it's clogged with debris (metabolic dysfunction)—the fire department keeps showing up, but the problem isn't a fire, it's the furnace itself. Neuroinflammation is smoke trapped in the basement (CNS) while the street-level (peripheral bloodwork) looks fine. Resolution-deficient inflammation is when the fire trucks arrived, sprayed water, but forgot to leave—they're still there weeks later, preventing reconstruction. Each requires a completely different response strategy: acute needs fast suppression, chronic needs trigger removal, metaflammation needs metabolic repair, neuroinflammation needs BBB-crossing interventions, resolution-deficient needs Specialized pro-resolving mediators (SPMs).
Pathogen/injury → DAMPs/PAMPs → TLR4 activation → NF-κB nuclear translocation → transcription of IL-1β, IL-6, TNF-α genes → massive cytokine release (IL-6 >20 pg/mL, TNF-α >50 pg/mL) → hepatic acute phase response → CRP >10 mg/L → neutrophil recruitment via CXCL1/IL-8 → neutrophilia (>7,500 cells/μL) → phagocytosis and pathogen clearance → normally resolves within 48-96 hours via SPM production (RvD1, RvE1, MaR1) → cessation of neutrophil influx → efferocytosis of apoptotic neutrophils by M2 macrophages → tissue repair initiation.
Persistent low-level triggers (obesity, chronic stress, gut dysbiosis, oral dysbiosis) → continuous but submaximal TLR4 stimulation → moderate NF-κB activation → sustained production of inflammatory mediators at lower amplitude (CRP 3-10 mg/L, IL-6 2-5 pg/mL) → macrophage polarization toward M1 phenotype → TNF-α and IL-1β production → impaired insulin signaling via JNK and IκB phosphorylation → insulin resistance → further adipose tissue dysfunction → vicious cycle. Characterized by failure of resolution mechanisms: inadequate SPM production (low 15-LOX, 5-LOX enzyme activity), impaired efferocytosis, persistent low-grade neutrophil presence.
Nutrient excess → adipocyte hypertrophy → hypoxia in expanding adipose tissue → HIF-1 activation → macrophage recruitment via CCL2 (MCP-1) → adipose tissue macrophage (ATM) accumulation → formation of crown-like structures around dying adipocytes → local TNF-α and IL-6 secretion → systemic spillover → hepatic Kupffer cell activation → free fatty acids acting as endogenous TLR4 agonists → hepatic inflammation → NASH development. Simultaneously: hyperglycemia → AGEs formation → RAGE receptor activation → additional NF-κB signaling → amplification loop.
CNS-specific triggers (chronic stress, gut dysbiosis, systemic inflammation) → peripheral cytokine entry via circumventricular organs or vagus nerve signaling → microglial activation → production of CNS-specific inflammatory mediators → may show normal peripheral CRP but elevated CNS markers (if CSF sampled) → blood-brain barrier disruption → further immune cell infiltration → astrocyte activation → glutamate dysregulation → potential neurodegeneration. Can occur independently of systemic inflammation.
Initial pathogen exposure (e.g., BCG vaccination, Candida) → monocyte/macrophage metabolic reprogramming → shift toward Aerobic Glycolysis → increased acetyl-CoA → histone acetylation at IL-6, TNF-α gene promoters → epigenetic memory in bone marrow progenitors → enhanced cytokine production (2-5× baseline) upon subsequent stimulation → can last 3-12 months → beneficial for pathogen defense but problematic if triggers are sterile/metabolic.
Phenotype identification guides intervention selection in cPNI practice. A patient with CRP >10 mg/L, IL-6 >20 pg/mL, and neutrophilia likely has acute inflammation requiring immediate pathogen identification and antimicrobial therapy—adding anti-inflammatory interventions too early may impair pathogen clearance. Conversely, CRP 3-5 mg/L chronically with mild IL-6 elevation (2-5 pg/mL) suggests lifestyle-driven chronic low-grade inflammation requiring diet modification (reduce AGEs, increase omega-3), stress management, sleep optimization, and gut barrier repair rather than pharmacological suppression.
Depression phenotyping: Approximately 30-40% of depression cases show elevated inflammatory markers (IL-6 >5 pg/mL, CRP >3 mg/L)—these patients respond poorly to SSRIs but may benefit from anti-inflammatory interventions (exercise, omega-3 at 2-4g/day EPA+DHA, curcumin 1000mg/day). The STAR*D trial failure rate correlates with lack of phenotype-specific treatment.
Metaflammation recognition is crucial for metabolic disease intervention. Patients with elevated fasting insulin (>10 μU/mL), HbA1c 5.7-6.4%, waist circumference >94cm (men) or >80cm (women), plus CRP 3-10 mg/L have metabolic inflammation—interventions must address root cause (insulin resistance, adipose dysfunction) via time-restricted eating, resistance training, HIIT, rather than merely suppressing inflammation with NSAIDs.
Resolution-deficient states (post-injury inflammation persisting >6 weeks, chronic wounds, fibromyalgia flares) may benefit from SPM supplementation or precursor loading: EPA/DHA 2-4g/day, aspirin 81mg (triggers ATL formation), specialized resolvin formulations if available. Traditional anti-inflammatories (NSAIDs, corticosteroids) may actually impair resolution by blocking COX-2-derived resolvins.
Evolutionary mismatch context: Chronic low-grade inflammation and metaflammation are quintessential mismatch diseases—Hunter-Gatherer Phenotype individuals rarely showed CRP >1 mg/L, while modern sedentary populations average 2-3 mg/L. The selfish immune system hypothesis explains persistent low-grade activation as adaptive pathogen defense in ancestral environments but maladaptive when sterile triggers (processed food, chronic stress, sedentary behavior) predominate.